2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.13A.02 Adebrelimab Combined with Famitinib and Chemotherapy as First-Line Therapy for ES-SCLC: A Phase II, Single-Arm Exploratory Research

EP.13A.02 Adebrelimab Combined with Famitinib and Chemotherapy as First-Line Therapy for ES-SCLC: A Phase II, Single-Arm Exploratory Research

Back to course

Pdf Summary

The document presents a study led by Zhao Yanbin at Harbin Medical University Cancer Hospital, China, investigating the combination of adebrelimab, famitinib, and chemotherapy for treating extensive-stage small cell lung cancer (ES-SCLC). Adebrelimab, combined with carboplatin and etoposide, has shown promising results in the first-line treatment for ES-SCLC. Famitinib, a tyrosine kinase inhibitor, targets multiple pathways to inhibit tumor growth and support immune system engagement.<br /><br />The study is designed as a multicenter, open-label, phase II trial involving 40 patients with pathologically confirmed ES-SCLC who have not undergone prior systemic therapy. Participants are aged 18 to 80 years, have a measurable tumor, a life expectancy of at least three months, and meet specific health criteria.<br /><br />The trial's primary endpoint is the 6-month progression-free survival (PFS) rate. Secondary endpoints include objective response rate (ORR), disease control rate (DCR), 12-month PFS rate, overall survival (OS), safety, and quality of life, assessed using the EORTC QLQ-C30.<br /><br />Treatment includes induction therapy with a combination of adebrelimab, etoposide, either cisplatin or carboplatin, and famitinib, followed by maintenance therapy with adebrelimab and famitinib. The study will monitor progression or any severe adverse reactions.<br /><br />Inclusion criteria require patients to have a normal organ function and ECOG performance status of 0-1, among others. Exclusion criteria include significant coagulation disorders, HIV positivity, uncontrollable brain metastases, severe uncontrolled illnesses, and unwillingness to adhere to the trial protocol.<br /><br />Contact information for inquiries is provided at the end of the document, highlighting Zhao Yanbin's email for further questions or comments.

Asset Subtitle

Yanbin Zhao

Meta Tag

Speaker Yanbin Zhao

Topic Small Cell Lung Cancer and Neuroendocrine Tumors

Keywords

Zhao Yanbin

Harbin Medical University

adebrelimab

famitinib

chemotherapy

extensive-stage small cell lung cancer

phase II trial

progression-free survival

EORTC QLQ-C30

tyrosine kinase inhibitor